KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E Adjustments
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization (IS) (2016 - 2025)

Historic Depreciation & Amortization (IS) for TherapeuticsMD (TXMD) over the last 13 years, with Q3 2025 value amounting to $96000.0.

  • TherapeuticsMD's Depreciation & Amortization (IS) changed 0.0% to $96000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $387000.0, marking a year-over-year decrease of 6300.19%. This contributed to the annual value of $509000.0 for FY2024, which is 4479.39% down from last year.
  • As of Q3 2025, TherapeuticsMD's Depreciation & Amortization (IS) stood at $96000.0, which was down 0.0% from $96000.0 recorded in Q2 2025.
  • TherapeuticsMD's 5-year Depreciation & Amortization (IS) high stood at $637000.0 for Q4 2023, and its period low was $27000.0 during Q1 2023.
  • Moreover, its 3-year median value for Depreciation & Amortization (IS) was $100000.0 (2024), whereas its average is $156181.8.
  • The largest annual percentage gain for TherapeuticsMD's Depreciation & Amortization (IS) in the last 5 years was 39259.26% (2024), contrasted with its biggest fall of 8430.14% (2024).
  • Quarter analysis of 3 years shows TherapeuticsMD's Depreciation & Amortization (IS) stood at $637000.0 in 2023, then tumbled by 84.3% to $100000.0 in 2024, then decreased by 4.0% to $96000.0 in 2025.
  • Its Depreciation & Amortization (IS) was $96000.0 in Q3 2025, compared to $96000.0 in Q2 2025 and $95000.0 in Q1 2025.